Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready to Start	Date of First Patient Recruited	Non- Confirmation Status	Duration between Date site selected and First Patient (days)	۱ - Permissions delayed/ enied	3 - Suspended by sponsor	: - Closed by sponsor	r - Sponsor Delays : - Staff availability issues	- No patients seen	3 - No patients consented	I - Contracting delays	- Rare diseases	- Other	Comments	Reasons for delay correspond to:
19/NW/0045	255691	I8B-MC-ITSB; A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog with an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes PRONTO-Peds	14/02/2019	10/04/2019	10/04/2019	24/04/2019	20/05/2019	03/06/2019	12/06/2019											•		
18/LO/0324	220073	The VIDEO Trial: A Feasibility Randomised Control Trial of Vitrectomy Plus Standard Care Intravitreal Ranibizumab Injections versus Standard Care Intravitreal Ranibizumab injections Alone In Patients With Centre Involving Diabetic Macular Edema		22/05/2019	03/04/2018	01/07/2019	01/07/2019	10/07/2019	27/09/2019		63						Y				Five participants were in screening, however first two participants were only recruited 27/09/2019	NHS Provider
18/EE/0222	233921	A randomised controlled trial of very early versus delayed angiography +/-intervention on outcomes in patients with non ST-elevation myocardial infarction		25/06/2019	12/09/2018	02/08/2019	02/08/2019	08/08/2019	16/08/2019		128											
19/LO/0452	250324	CASTLE: Randomised factorial design controlled trial comparing carbamazepine, levetiracetam or active monitoring combined with or without sleep behaviour intervention in treatment naive children with rolandic epilepsy		08/08/2019	02/05/2019	10/09/2019	17/09/2019	04/10/2019	11/02/2020		187						Υ				Four participants were screened and approached, however participants rejected the study. Site continued to screen and approach potential participants and recruited the first patient in February 2020. Trial has since been closed early due to low numbers, trial in the process of being redesigned	NHS Provider

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready to Start	Date of First Patient Recruited	Non- Confirmation Status	Duration between Date site selected and First Patient (days)	۱ - Permissions delayed/ lenied	: - Closed by sponsor	₩.	: - No patients seen	3 - No patients consented	1 - Contracting delays	- Rare diseases	I - Other	Comments	Reasons for delay correspond to:
18/YH/0358	242342	Sunflower: A randomised controlled trial to establish the clinical and cost effectiveness of expectant management versus pre-operative imaging with Magnetic Resonance Cholangiopancreatography (MRCP) in patients with symptomatic gallstones undergoing laparoscopic cholecystectomy at low or moderate risk of common bile duct stones	15/08/2018	28/05/2019	12/12/2018	28/05/2019	22/08/2019	23/08/2019	04/09/2019		99			Y		0			s	Delays to SIV due to lack of staff availability from NHS Provider	NHS Provider
19/LO/0236 (a)	230338	The Effect of Higher Protein Dosing in Critically III Patients: A Multicenter Registry-based Randomized Trial - The EFFORT Trial	25/04/2019	11/09/2019	01/07/2019	06/12/2019	10/12/2019	11/12/2019	08/01/2020		119		Y						a a R	sponsor delays with HRA approval for our site to be added (This record is for St Richard's Hospital Principal nvestigator site)	Sponsor
19/LO/0236 (b)	230338	The Effect of Higher Protein Dosing in Critically III Patients: A Multicenter Registry-based Randomized Trial - The EFFORT Trial	25/04/2019	11/09/2019	01/07/2019	06/12/2019	10/12/2019	11/12/2019	22/01/2020		133		Y						a a V	Sponsor delays with HRA spproval for our site to be added (This record is for Worthing Hospital's Principal Investigator site)	Sponsor
19/NE/0215	234453	Myeloma XIV (FiTNEss). Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I).	28/06/2019	02/12/2019	07/11/2019	22/01/2020	19/02/2020	06/08/2020	29/09/2020		302		Y						ri h f d f t iii p t	The Sponsor were not ready to open sites; they noped to open sites in rebruary 2020. Sponsor due to open sites in February 2020, however this got delayed futher and in March 2020 the Sponsor out this study on hold due to the global pandemic. First pateint recruited after restart at site (August 2020)	Sponsor
20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	17/03/2020	17/03/2020	17/03/2020	13/03/2020	25/03/2020	25/03/2020	01/04/2020		15										